Light-Sensitive Ruthenium Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of Cancer
- PMID: 26855780
- PMCID: PMC4739781
- DOI: 10.1039/C5TB01613D
Light-Sensitive Ruthenium Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of Cancer
Abstract
This work focuses on improving the efficacy of photoactivatable Ru complexes for photodynamic therapy by employing cross-linked nanoassemblies (CNAs) as a delivery approach. The effects of complex photoactivation, hydrophobicity, and solution ionic strength and pH on complex loading and release from CNAs were analyzed. The cell cytotoxicity of CNA formulations was similar to free Ru complexes despite reduced or eliminated DNA interactions. The release rate and the amount of each Ru complex released (%) varied inversely with complex hydrophobicity, while the effect of solution ionic strength was dependent on complex hydrophobicity. Premature release of two photoactivatable prodrugs prior to irradiation was believed to account for higher activity in cells studies compared to DNA interaction studies; however, for photostable 1O2 generator-loaded CNAs this cannot explain the high cytotoxicity and lack of DNA interactions because release was incomplete after 48 hrs. The cause remains unclear, but among other possibilities, accelerated release in a cell culture environment may be responsible.
Figures
























Similar articles
-
Noncovalent Ruthenium(II) Complexes-Single-Walled Carbon Nanotube Composites for Bimodal Photothermal and Photodynamic Therapy with Near-Infrared Irradiation.ACS Appl Mater Interfaces. 2015 Oct 21;7(41):23278-90. doi: 10.1021/acsami.5b07510. Epub 2015 Oct 8. ACS Appl Mater Interfaces. 2015. PMID: 26430876
-
Nuclear targets of photodynamic tridentate ruthenium complexes.Dalton Trans. 2009 Dec 28;(48):10926-31. doi: 10.1039/b913959a. Epub 2009 Nov 16. Dalton Trans. 2009. PMID: 20023923
-
trans-[Ru(NO)Cl(cyclam)](PF6)2 and [Ru(NO)(Hedta)] incorporated in PLGA nanoparticles for the delivery of nitric oxide to B16-F10 cells: cytotoxicity and phototoxicity.Mol Pharm. 2013 Oct 7;10(10):3544-54. doi: 10.1021/mp3005534. Epub 2013 Aug 28. Mol Pharm. 2013. PMID: 23865934
-
PEGylated FePt-Fe3O4 composite nanoassemblies (CNAs): in vitro hyperthermia, drug delivery and generation of reactive oxygen species (ROS).Dalton Trans. 2015 May 21;44(19):9103-13. doi: 10.1039/c4dt03470h. Dalton Trans. 2015. PMID: 25897960
-
Preparation of organometallic ruthenium-arene-diaminotriazine complexes as binding agents to DNA.Chem Asian J. 2012 Apr;7(4):788-801. doi: 10.1002/asia.201100883. Epub 2012 Feb 3. Chem Asian J. 2012. PMID: 22308008
Cited by
-
Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.J Am Chem Soc. 2022 May 11;144(18):8317-8336. doi: 10.1021/jacs.2c02475. Epub 2022 Apr 28. J Am Chem Soc. 2022. PMID: 35482975 Free PMC article.
-
Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.Photochem Photobiol. 2022 Jan;98(1):102-116. doi: 10.1111/php.13508. Epub 2021 Nov 13. Photochem Photobiol. 2022. PMID: 34411308 Free PMC article.
-
Comparison of Dialysis- and Solvatofluorochromism-Based Methods to Determine Drug Release Rates from Polymer Nanoassemblies.Pharm Res. 2017 Feb;34(2):394-407. doi: 10.1007/s11095-016-2070-6. Epub 2016 Nov 21. Pharm Res. 2017. PMID: 27873146
-
Development of Halofluorochromic Polymer Nanoassemblies for the Potential Detection of Liver Metastatic Colorectal Cancer Tumors Using Experimental and Computational Approaches.Pharm Res. 2017 Nov;34(11):2385-2402. doi: 10.1007/s11095-017-2245-9. Epub 2017 Aug 24. Pharm Res. 2017. PMID: 28840432 Free PMC article.
-
111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells.Nanoscale. 2018 Jun 7;10(22):10596-10608. doi: 10.1039/c7nr09606b. Nanoscale. 2018. PMID: 29808844 Free PMC article.
References
-
- Howerton BS, Heidary DK, Glazer EC. Strained ruthenium complexes are potent light-activated anticancer agents. J Am Chem Soc. 2012;134:8324–8327. - PubMed
- Dickerson M, Sun Y, Howerton B, Glazer EC. Modifying charge and hydrophilicity of simple Ru(II) polypyridyl complexes radically alters biological activities: old complexes, surprising new tricks. Inorg Chem. 2014;53(19):10370–7. - PMC - PubMed
-
- Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol. 2003;7:481–489. - PubMed
- Fricker SP. Metal based drugs: from serendipity to design. Dalton Trans. 2007;43:4903–4917. - PubMed
- Bruijnincx PCA, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol. 2008;12:197–206. - PMC - PubMed
- Chen T, Liu Y, Zheng WJ, Liu J, Wong YS. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Inorg Chem. 2010;49:6366–6368. - PubMed
- Groessl M, Zava O, Dyson PJ. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics. 2011;3:591–599. - PubMed
-
- Goldbach RE, Rodriguez-Garcia I, van Lenthe JH, Siegler MA, Bonnet S. N-acetylmethionine and biotin as photocleavable protective groups for ruthenium polypyridyl complexes. Chem Eur J. 2011;17:9924–9929. - PubMed
- Wachter E, Heidary DK, Howerton BS, Parkin S, Glazer EC. Light-activated ruthenium complexes photobind DNA and are cytotoxic in the phtodynamic therapy window. Chem Commun. 2012;48:9649–9651. - PubMed
- Frasconi M, Liu Z, Lei J, Wu Y, Strekalova E, Malin D, Ambrogio MW, Chen X, Botros YY, Cryns VL, Sauvage JP, Stoddart JF. Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc. 2013;135:11603–11613. - PMC - PubMed
- Hufziger KT, Thowfeik FS, Charboneau DJ, Nieto I, Dougherty WG, Kassel WS, Dudley TJ, Merino EJ, Papish ET, Paul JJ. Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release. J Inorg Biochem. 2014;130:103–111. - PMC - PubMed
-
- Novakova O, Kasparkova J, Vrana O, van Vliet PM, Reedijk J, Brabec V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry. 1995;34:12369–12378. - PubMed
- Kladjner M, Hebraud P, Sirlin C, Gaiddon C, Harlepp S. DNA binding to an anticancer organo-ruthenium complex. J Phys Chem. 2010;114:14041–14047. - PubMed
- Heidary DK, Glazer EC. A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay. ChemBioChem. 2014;15:507–511. - PubMed
-
- Grover N, Welch TW, Fairley TA, Cory M, Thorp HH. Covalent Binding of Aquaruthenium complexes to DNA. Inorg Chem. 1994;33:3544–3548.
- Allardyce CS, Dyson PJ. Ruthenium in medicine: Current clinical uses and future prospects. Platinum Metals Rev. 2001;45:62–69.
- Lentzen O, Moucheron C, Kirsch-De Mesmaeker A. Metallotherapeutic drugs and metal-based diagnostic agents. John Wiley & Sons, Ltd; 2005. 44Ru Perspectives of ruthenium complexes in cancer therapy; pp. 359–378.
- Boerner LJK, Zaleski JM. Metal complex-DNA interactions: from transcription inhibition to photoactivated cleavage. Curr Opin Chem Biol. 2005;9:135–144. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources